- Fundraise significantly surpasses target
- Underpinned by strong commitments from longstanding and new globally diversified investors
- Demonstrates investors’ confidence in Exponent’s differentiated and long-standing strategy in the UK, Ireland, and the Benelux mid-market
- Builds on Exponent’s proven strategy of investing in corporate, family and founder owned businesses (“primaries”) with the potential to double profits through revenue-driven growth levers
- Fund V has already made four high-quality investments
London and Dublin, 9 July 2025 – Exponent, a leading European private equity firm, today announced the final close of its fifth fund, Exponent Private Equity Partners V (“Fund V”), with £900 million in commitments (equivalent to more than €1 billion), 20 per cent above its target.
Fund V attracted strong support from a globally diversified investor base, with commitments from longstanding partners and new investors across North America, Europe, the Middle East and Asia. The investor base includes pension funds, endowments, sovereign wealth funds, family offices and other leading institutional investors.
Fund V will continue Exponent’s strategy of investing in high-quality mid-market businesses. Over the past 15 years, Exponent has focused exclusively on corporate, family and founder owned businesses of scale (“primaries”), which are already established leaders in their markets. As the first private equity owner, Exponent identifies the potential to double profits through several, revenue-driven, growth levers and has an established track record of achieving this with its portfolio companies.
Marius Østlie, Partner at Exponent, said: “We’re grateful for the continued support of our longstanding partners and pleased to welcome a number of new investors to Fund V. The response to this fundraise reflects strong conviction in our team, track record and disciplined strategy. We look forward to building long-term relationships with our new LPs and continuing to deliver value for all our partners.”
Richard Lenane, Managing Partner at Exponent, said: “We have a truly differentiated mid-market strategy which has consistently delivered value for our investors and management teams throughout economic cycles. Our ability to identify the potential for revenue driven profit growth makes us an attractive and trusted partner for corporates, families and founders. Fund V allows us to continue executing this strategy which is underpinned by discipline, sub-sector expertise and operational rigour.”
Fund V has completed four investments so far: Chanelle Pharma, a European leader in generic and veterinary pharmaceuticals; Ethos Engineering, a specialist in sustainable, mission-critical data centre design; Kingsbridge Healthcare Group, the largest private healthcare provider in Northern Ireland, and the only hospital operator across both Northern Ireland and the Republic of Ireland; and Hippo Digital, a fast-growing technology consultancy focused on user-centred digital transformation.
Exponent was advised on the fundraise by Rede Partners LLP with Debevoise & Plimpton LLP serving as legal counsel.